Literature DB >> 7905389

Toxicokinetics of sulfasalazine (salicylazosulfapyridine) and its metabolites in B6C3F1 mice.

W Zheng1, S M Winter, M Mayersohn, J B Bishop, I G Sipes.   

Abstract

The toxicokinetics of salicylazosulfapyridine (SASP) and its metabolites were investigated in male and female B6C3F1 mice either following single intravenous (5 mg/kg) or oral (67.5, 675, 1350, and 2700 mg/kg) doses, or following three consecutive daily oral doses (675, 1350, and 2700 mg/kg). Plasma concentrations of SASP and its metabolites were quantified by HPLC. Upon intravenous administration, SASP rapidly disappeared from blood with a mean residence time of 0.45-0.78 hr. The only metabolite of SASP found in plasma after an intravenous dose was sulfapyridine (SP). In both sexes, the absolute oral bioavailability of SASP ranged between 16.6-18.2% at a dose of 67.5 mg/kg, and between 2.6-8.7% at doses of 675-2700 mg/kg. Following oral administration of SASP, both SP and AcSP were identified in plasma. The area under the plasma concentration-time curves (AUC) of SP at all four oral doses were approximately 21- to 32-fold or 5- to 25-fold greater than those of SASP in male or female mice, respectively. The acetylated form of SP and AcSP, produced AUC values higher than SASP but much less than SP. Multiple oral doses with SASP did not alter the temporal patterns of SASP absorption and elimination in comparison to a single dose. However, SP accumulated in both sexes following multiple oral doses. A gender-dependent difference in toxicokinetic profiles for SASP and SP was also observed. Female mice displayed a higher Cmax of SASP and SP than did male mice. Although the volume of distribution of SASP was similar in both sexes, the systemic clearance of SASP in males was about twice that observed in females.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7905389

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  8 in total

1.  Sulfasalazine for brain cancer fits.

Authors:  Harald Sontheimer; Richard J Bridges
Journal:  Expert Opin Investig Drugs       Date:  2012-03-12       Impact factor: 6.206

2.  Enhancement of Radiation Response in Breast Cancer Stem Cells by Inhibition of Thioredoxin- and Glutathione-Dependent Metabolism.

Authors:  Samuel N Rodman; Jacquelyn M Spence; Tyler J Ronnfeldt; Yueming Zhu; Shane R Solst; Rebecca A O'Neill; Bryan G Allen; Xiangming Guan; Douglas R Spitz; Melissa A Fath
Journal:  Radiat Res       Date:  2016-09-19       Impact factor: 2.841

3.  Evaluation of the usefulness of breast cancer resistance protein (BCRP) knockout mice and BCRP inhibitor-treated monkeys to estimate the clinical impact of BCRP modulation on the pharmacokinetics of BCRP substrates.

Authors:  Tsuyoshi Karibe; Rie Hagihara-Nakagomi; Koji Abe; Tomoki Imaoka; Tsuyoshi Mikkaichi; Satoru Yasuda; Masakazu Hirouchi; Nobuaki Watanabe; Noriko Okudaira; Takashi Izumi
Journal:  Pharm Res       Date:  2014-11-08       Impact factor: 4.200

4.  Toxicokinetics of tremorogenic natural products, harmane and harmine, in male Sprague-Dawley rats.

Authors:  Y Guan; E D Louis; W Zheng
Journal:  J Toxicol Environ Health A       Date:  2001-12-21

Review 5.  Main path and byways: non-vesicular glutamate release by system xc(-) as an important modifier of glutamatergic neurotransmission.

Authors:  Ann Massie; Séverine Boillée; Sandra Hewett; Lori Knackstedt; Jan Lewerenz
Journal:  J Neurochem       Date:  2015-09-29       Impact factor: 5.372

6.  Chronic Sulfasalazine Treatment in Mice Induces System xc - - Independent Adverse Effects.

Authors:  Lise Verbruggen; Lindsay Sprimont; Eduard Bentea; Pauline Janssen; Azzedine Gharib; Lauren Deneyer; Laura De Pauw; Olaya Lara; Hideyo Sato; Charles Nicaise; Ann Massie
Journal:  Front Pharmacol       Date:  2021-05-18       Impact factor: 5.810

7.  Glutamate release by primary brain tumors induces epileptic activity.

Authors:  Susan C Buckingham; Susan L Campbell; Brian R Haas; Vedrana Montana; Stefanie Robel; Toyin Ogunrinu; Harald Sontheimer
Journal:  Nat Med       Date:  2011-09-11       Impact factor: 53.440

8.  Sulfasalazine decreases astrogliosis-mediated seizure burden.

Authors:  Oscar Alcoreza; Sai Jagarlamudi; Andrew Savoia; Susan L Campbell; Harald Sontheimer
Journal:  Epilepsia       Date:  2022-02-07       Impact factor: 6.740

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.